Učitavanje...
Intravitreal Bevacizumab for Treatment of Refractory Central Serous Choroidoretinopathy
In a clinical case series, 5 patients with not-resolved central serous choroidoretinopathy (CSC) lasting more than 1 year received one intravitreal bevacizumab injection (IVB, 1.25 mg) injection. All patients underwent a through ophthalmic examination 1 day, 1 week, and 1, 2, and 6 months after the...
Spremljeno u:
| Glavni autori: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The Korean Ophthalmological Society
2012
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3325620/ https://ncbi.nlm.nih.gov/pubmed/22511842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3341/kjo.2012.26.2.139 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|